MarketPulse

heart failure

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

SynCardia's Emperor Heart Set to Challenge Artificial Organ Market at Major Cardiology Conference

SynCardia unveils next-generation Emperor artificial heart at major cardiology conference, advancing fully implantable technology for long-term heart failure treatment.
PMIheart failuretotal artificial heart
GlobeNewswire Inc.GlobeNewswire Inc.··Picard Medical, Inc.

SynCardia's Artificial Heart Technology Takes Center Stage on FOX Business

Picard Medical's SynCardia Systems showcases its Total Artificial Heart technology on FOX Business, highlighting over 2,100 implants worldwide.
PMIFDA approvalheart failure
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials